Non-inferiority Study to Compare the Efficacy and Safety of Mylan's Insulin Glargine With Lantus® in Type 2 Diabetes Mellitus Patients (INSTRIDE 2)
A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 560 participants.
Also called NCT02227875
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; no masking; primary purpose treatment
- Phase
- Phase 3
- Enrolled
- 560 participants
- Sponsor
- Mylan Inc.
- Registry
-
NCT02227875
-
- Start date
- (registry gives no type)
- Primary completion
- (actual)
- Completion
- (actual)
- Results first posted
- Countries
- United States, Jordan, Slovakia, South Africa, South Korea, Taiwan
- Registry status
- Completed
Technical summary
Registry record NCT02227875. Randomized; no masking; primary purpose treatment. Start 2014-08 (registry gives no type); primary completion 2015-12 (actual). Results posted on 2020-08-13.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- Non-inferiority Study to Compare the Efficacy and Safety of Mylan's Insulin Glargine With Lantus® in Type 2 Diabetes Mellitus Patients (INSTRIDE 2)
- Acronym
- INSTRIDE 2
- Condition
- Type 2 Diabetes
- Intervention (Drug)
- Mylan's insulin glargine
- Intervention (Drug)
- Lantus®
- Lead sponsor
- Mylan Inc.
- Collaborator
- Mylan GmbH
Record details
- Record id
cardio:ct-nct02227875- Content hash
ae12d6659a81b84031caca664d96c9c4934d58449bcf39b116a1377a33a7afa6